Drug Trial Radar · NCT02353949
Investigating the Clinical Consequences of Flutemetamol-PET-scanning
Last checked: Nov 20, 2026Latest source record: Jan 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
11
Actual
Start
May 2015
Primary completion
Dec 10, 2019
Study completion Dec 10, 2019
Sponsor
- Lead sponsor
- University of ZurichAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ETH Zurich
- First posted
- Feb 3, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study examines subjects where there might be an indication for Amyloid-PET according to the Criteria defined by the Amyloid Imaging Task Force. In these subjects the impact of a Flutemetamol (Vizamyl)-Positron-Emission-Tomography -Scan (PET) on clinical management and disease course will be studied over 6 months.
Conditions
- Mild Cognitive Impairment
- Alzheimer's Disease
- Dementia
Interventions
Flutemetamol (Vizamyl)Drug
PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of ADAS-cog 11 score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.Time frame: Three months after initiation of standard treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Zurich, Institute for Regenerative Medicine, Center for Prevention and Dementia Therapy
Schlieren, Canton of Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.